-

Graphic Packaging Holding Company Class Action Reminder - Robbins LLP Encourages GPK Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP is Investigating Allegations that Graphic Packaging Holding Company (GPK) Misled Investors Regarding its Inventory Management Issues.

Robbins LLP is Investigating Allegations that Graphic Packaging Holding Company (GPK) Misled Investors Regarding its Inventory Management Issues

Share

On May 7, 2026, a class action was filed on behalf of all investors who purchased or otherwise acquired Graphic Packaging Holding Company (NYSE: GPK) common stock between February 4, 2025 and February 2, 2026. Graphic Packaging, together with its subsidiaries, designs, produces, and sells consumer packaging products.

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

What is the class period? February 4, 2025 - February 2, 2026

What are the allegations? According to the complaint, during the class period, defendants failed to disclose that:

  • Graphic Packaging was experiencing, inter alia, significant inventory management issues, as well as significantly reduced demand and volumes and increased costs;
  • Defendants downplayed the true scope and severity of the foregoing issues, which were likely to, and did, have a material negative impact on the Company’s business and financial results;
  • Defendants likewise overstated the strength and sustainability of the Company’s business model and operations, as well as its ability to weather ongoing macroeconomic headwinds; and
  • Accordingly, the Company’s previously issued FY 2025 financial guidance was unreliable and/or unrealistic.

Plaintiff alleges that on February 3, 2026, Graphic Packaging reported disappointing fourth quarter (“Q4”) and FY 2025 financial results. Specifically, Graphic Packaging

  • Reported Q4 non-GAAP EPS of $0.29, missing consensus estimates by $0.06, attributable to, inter alia, lower volumes, increased costs, and inventory reduction.
  • Projected a meaningful decline in adjusted EBITDA in 2026, citing “a $130 million negative impact from actions taken to reduce inventory and generate [FCF], an approximately $100 million accrual (non-cash in 2026) for a return to more normal incentive compensation, January weather and production impacts, and other largely offsetting operating items.”
  • Announced that new President and CEO, Robbert Rietbroek, had “initiated a comprehensive review of our organization structure, operations, and footprint,” among other aspects of the Company’s business, thereby confirming the weakness and unsustainability of its present business model and operations.

On this news, Graphic Packaging’s stock price fell $2.36 per share, or 15.97%, to close at $12.42 per share on February 3, 2026.

What can shareholders do now? You may be eligible to participate in the class action against Graphic Packaging Holding Company. Shareholders who wish to serve as lead plaintiff for the class must submit their papers with the court by July 6, 2026. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002.

To be notified if a class action against Graphic Packaging Holding Company settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NYSE:GPK

Release Versions
$Cashtags

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

Stockholder Alert: Robbins LLP Informs Investors of the Flotek Industries, Inc. (FTK) Class Action

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Flotek Industries, Inc. (NYSE: FTK) securities between August 3, 2026 and August 17, 2026 (the "Class Period"). Flotek is an energy technology and services company.The complaint alleges that Flotek misled investors by failing to disclose the cancellation of its $400m Puerto Rican deal.Investors who suffered s...

Robbins LLP Encourages WSE Stockholders with Large Losses to Seek Counsel for the Securities Class Action Lawsuit Against Wise Group plc

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Wise Group plc (NASDAQ: WSE) securities between May 11, 2026 and July 23, 2026 (the "Class Period").The complaint alleges that Wise and certain of its senior executives violated the federal securities laws by making materially false and/or misleading statements regarding the Company's anti-money laundering compliance, a...

Robbins LLP Urges Investors of ARS Pharmaceuticals Inc. to Contact the Firm for Information About the SPRY Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds shareholders that a securities class action has been filed on behalf of all investors who purchased or otherwise acquired ARS Pharmaceuticals Inc. (NASDAQ: SPRY) securities between March 9, 2026 and June 24, 2026 (the "Class Period"). ARS is a clinical stage biopharmaceutical company focused on the development and commercialization of neffy for needle-free intranasal delivery of epinephrine for emergency treatment of Type 1 allergic reactions, incl...
Back to Newsroom